U.S. flag An official website of the United States government
  1. Home
  2. For Industry
  3. FDA User Fee Programs
  4. Prescription Drug User Fee Amendments
  5. Upcoming EL-PFDD Meetings
  1. Prescription Drug User Fee Amendments

Upcoming EL-PFDD Meetings

To promote transparency and communication, FDA is sharing a list of disease areas where a letter of intent (LOI) has been submitted and ongoing plans exist for a future Externally-Led PFDD meeting. While multiple organizations may be working together, the organizations listed below are the primary points of contact for any questions regarding their EL-PFDD meeting.

FDA does not conduct Externally-Led PFDD meetings and a listing on this webpage does not reflect endorsement.

Disease or Condition

Organization Submitting LOI

Organization Contact

Anticipated Meeting Date

Rare, Autoimmune Peripheral Neuropathies: Guillain-Barre Syndrome (GBS), Multifocal Motor Neuropathy (MMN), and Anti-myeline-associated glycoprotein (Anti-MAG) neuropathy

GBS|CIDP Foundation International

Chelsey Fix


May 16, 2024

Peroxisomal Disorders

The Global Foundation for Peroxisomal Disorders

Melissa Bryce


May 28, 2024

Adult Dermatomyositis (DM) Myositis Support and Understanding

Lynn Wilson


June 7, 2024
Long QT Syndrome (LQTS) and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) SADS Foundation

Genevie Echols


June 11, 2024
Classic Congenital Adrenal Hyperplasia (CAH) CARES Foundation

Dina Matos


October 1, 2024
Lupus Nephritis (LN) National Kidney Foundation

David Feldman


October 11, 2024
Dementia with Lewy Bodies (DLB) Lewy Body Dementia Association

Glorieuse Norzea


October 15, 2024
Sarcoidosis Foundation for Sarcoidosis Research

Tricha Shivas


October 28, 2024

Angelman Syndrome

Foundation for Angelman Syndrome Therapeutics (FAST) and the Angelman Syndrome Foundation (ASF)

Amanda Moore and Ryan Fischer


January 29, 2025


To contact FDA’s CDER Patient-Focused Drug Development Program Staff, please email patientfocused@fda.hhs.gov.

To get updates about CDER's Patient-Focused Drug Development programs, subscribe to our free email subscription service using the button at the top of the page.

Back to CDER Patient-Focused Drug Development Homepage.

Back to Top